CGD gene therapy (Georg-Speyer-Haus)

N/A

Report date: 2022/03/29 18:01:19

Base Information

Drug NameCGD gene therapy (Georg-Speyer-Haus)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionNADPH oxidase inhibitors
TargetsNADPH oxidase
Therapy Area/IndicationsGranulomatous Disease, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGeorg-Speyer-Haus
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGeorg-Speyer-Haus
Active IndicationsN/A
Inactive IndicationsGranulomatous Disease, Chronic

Other Information

ATC CodeN/A
Related LinksN/A